Non-Hodgkin's Lymphoma Market Trends, Challenges, Opportunities and Forecasts to 2024

Submitted by: Submitted by

Views: 10

Words: 916

Pages: 4

Category: Business and Industry

Date Submitted: 02/29/2016 10:14 PM

Report This Essay

Non-Hodgkin's Lymphoma Market Current Trends, Size, Share, Industry

Analysis, Competitive Intelligence, Growth, Opportunities and Forecasts To

2024

Summary

Non-Hodgkin's Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic

system. In NHL, the body's immune system is affected by the uncontrollable growth of

malignant white blood cells, resulting in the body's inability to fight infections and other

diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte

lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL:

follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and

mantle cell lymphoma. NHL is more common in men than in women, in white men and women

compared with black men and women, and the incidence exponentially increases with age.

GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell NHL in

the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual

growth rate (AGR) of 2.32%. Throughout the forecast period, the US will have the highest

number of incident cases of B-cell NHL, as well as 36% growth during the forecast period,

ending with 57,724 incident cases in 2024. Additionally, each of the 7MM will see an increase in

incident cases over the 10-year forecast period.

Browse the full “Non-Hodgkin's Lymphoma Market” report at:

http://www.radiantinsights.com/research/epicast-report-non-hodgkin-s-lymphomaepidemiology-forecast-to-2024

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and countryspecific disease databases to construct the 10-year epidemiological forecast for the incident cases

of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the

7MM. A major strength of GlobalData's epidemiological analysis is the exclusive use of countryspecific sources, allowing for a meaningful...